Sodium 5-(3-ethynylphenylamino)pyrimido[4,5-c]quinoline-8-carboxylate

CX-5011 is a CK2 inhibitor. CX-5011 also induces Rac1 activation. CX-5011 induces apoptosis and induces cancer cell death[1][2].

[1] D'Amore C, et al. "Janus" efficacy of CX-5011: CK2 inhibition and methuosis induction by independent mechanisms. Biochim Biophys Acta Mol Cell Res. 2020 Nov;1867(11):118807. DOI:10.1016/j.bbamcr.2020.118807
[2] Salizzato V, et al. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. Oncotarget. 2016 Apr 5;7(14):18204-18. DOI:10.18632/oncotarget.7569